AZD 4818

Drug Profile

AZD 4818

Alternative Names: AZD4818

Latest Information Update: 13 Oct 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Class
  • Mechanism of Action CCR1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Chronic obstructive pulmonary disease

Most Recent Events

  • 16 Sep 2009 Pharmacodynamics data from a preclinical trial in Chronic obstructive pulmonary disease presented at the 19th Annual Congress of the European Respiratory Society (ERS-2009)
  • 16 Sep 2009 Efficacy and adverse events data from a phase II trial in Chronic obstructive pulmonary disease presented at the 19th Annual Congress of the European Respiratory Society (ERS-2009)
  • 29 Jan 2009 Discontinued - Phase-I for Chronic obstructive pulmonary disease in Japan (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top